Literature DB >> 23400731

[Subjective grading of Barrett's neoplasia by pathologists: correlation with objective histomorphometric variables].

E Sabo1, G Klorin, E Montgomery, K C Drumea, O Ben-Izhak, J Lachter, M Vieth.   

Abstract

Even though pathologists are trained to recognize the same histological features for the diagnosis and grading of different histological images, not all pathologists are influenced to a similar level of intensity by the same morphological characteristics of the tissue when scoring Barrett's dysplasia/neoplasia. The variables which most pathologists have intuitively chosen to use for scoring of the severity of Barrett's changes are mainly those related to the general tissue architecture, such as nuclear crowding, orientation and stratification. Interestingly, nuclear size is not used by most pathologists but nuclear pleomorphism and symmetry does influence a significant number of pathologists. Maybe the most difficult variables for the human eye to recognize are variables of chromatin texture (such as margination or heterogeneity), the predictive importance of which has been demonstrated in a previously published work. Textural variables may therefore remain the subject of a computerized analysis. Nevertheless, the fact that a few pathologists do actually correlate with nuclear texture in scoring, argues in favor of making further attempts to train pathologists to also rely on texture, similar to cytologists, when scoring Barrett's dysplasia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23400731     DOI: 10.1007/s00292-012-1732-3

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  23 in total

Review 1.  Pathology of Barrett's esophagus.

Authors:  R C Haggitt
Journal:  J Gastrointest Surg       Date:  2000 Mar-Apr       Impact factor: 3.452

Review 2.  The diagnosis of dysplasia and malignancy in Barrett's oesophagus.

Authors:  K Geboes; P Van Eyken
Journal:  Histopathology       Date:  2000-08       Impact factor: 5.087

Review 3.  The molecular biology of esophageal adenocarcinoma.

Authors:  Linetta B Koppert; Bas P L Wijnhoven; Herman van Dekken; Hugo W Tilanus; Winand N M Dinjens
Journal:  J Surg Oncol       Date:  2005-12-01       Impact factor: 3.454

4.  Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation.

Authors:  W Polkowski; J P Baak; J J van Lanschot; G A Meijer; L T Schuurmans; F J Ten Kate; H Obertop; G J Offerhaus
Journal:  J Pathol       Date:  1998-02       Impact factor: 7.996

Review 5.  Diagnosis and grading of dysplasia in Barrett's oesophagus.

Authors:  R D Odze
Journal:  J Clin Pathol       Date:  2006-10       Impact factor: 3.411

6.  Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Authors:  P S Rabinovitch; G Longton; P L Blount; D S Levine; B J Reid
Journal:  Am J Gastroenterol       Date:  2001-11       Impact factor: 10.864

7.  Grading of gastric foveolar-type dysplasia in Barrett's esophagus.

Authors:  Dipti Mahajan; Ana E Bennett; Xiaobo Liu; James Bena; Mary P Bronner
Journal:  Mod Pathol       Date:  2009-10-16       Impact factor: 7.842

Review 8.  Barrett's esophagus: histopathologic definitions and diagnostic criteria.

Authors:  James Mueller; Martin Werner; Manfred Stolte
Journal:  World J Surg       Date:  2004-01-20       Impact factor: 3.352

Review 9.  Barrett's esophagus, dysplasia, and adenocarcinoma.

Authors:  R C Haggitt
Journal:  Hum Pathol       Date:  1994-10       Impact factor: 3.466

Review 10.  Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia.

Authors:  Kaiyo Takubo; Michael Vieth; Junko Aida; Motoji Sawabe; Yoichi Kumagai; Yoshio Hoshihara; Tomio Arai
Journal:  Digestion       Date:  2009-10-15       Impact factor: 3.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.